GlassScriptPhysician profile
Daniel R Pilosov
NPI 1013092006
$3,075.98
in general payments reported to CMS, 2019-2025
12 companies · $275 in 2025
The $275 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $233 · 2020: $276 · 2021: $797 · 2022: $546 · 2023: $541 · 2024: $408 · 2025: $275.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,224.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,223.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,709.33 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Abbvie INC. | $637.65 | 2021-2024 | |
| Lilly USA, LLC | $259.05 | 2019-2025 | Mounjaro, Zepbound |
| Intra-Sana Laboratories | $136.94 | 2023 | Reltone 400 Mg, Reltone 200 Mg, Glycate |
| Glaxosmithkline, LLC. | $106.98 | 2022-2025 | Bexsero, Rotarix, Pediarix |
| Merck Sharp & Dohme LLC | $55.94 | 2023-2025 | Pifeltro, Delstrigo |
| Amarin Pharma, INC. | $41.89 | 2019-2021 | |
| Viiv Healthcare Company | $40.57 | 2024-2025 | Apretude |
| Bayer Healthcare Pharmaceuticals INC. | $33.40 | 2025 | |
| Sanofi-Aventis U.S. LLC | $23.82 | 2021 | |
| Pfizer INC. | $15.62 | 2024 | |
| Emd Serono, INC. | $14.79 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Pilosov listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.